Defining Discontinuation for Buprenorphine Treatment: Implications for Quality Measurement
2024; American Psychiatric Association; Volume: 181; Issue: 5 Linguagem: Inglês
10.1176/appi.ajp.20230808
ISSN1535-7228
AutoresArthur Robin Williams, Christine Mauro, Ben Huber, Lisa M. Chiodo, Stephen Crystal, Hillary Samples, Mark Olfson,
Tópico(s)Forensic Toxicology and Drug Analysis
ResumoBack to table of contents Previous article Next article Priority Data LetterNo AccessDefining Discontinuation for Buprenorphine Treatment: Implications for Quality MeasurementArthur Robin Williams, M.D., M.B.E., Christine M. Mauro, Ph.D., Ben Huber, M.S., Lisa Chiodo, Ph.D., Stephen Crystal, Ph.D., Hillary Samples, Ph.D., Mark Olfson, M.D., M.P.H.Arthur Robin Williams, M.D., M.B.E., Christine M. Mauro, Ph.D., Ben Huber, M.S., Lisa Chiodo, Ph.D., Stephen Crystal, Ph.D., Hillary Samples, Ph.D., Mark Olfson, M.D., M.P.H.Published Online:6 May 2024https://doi.org/10.1176/appi.ajp.20230808AboutSectionsView articleView Full TextSupplemental MaterialPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail View article Access content To read the fulltext, please use one of the options below to sign in or purchase access. Personal login Institutional Login Sign in via OpenAthens Register for access Purchase Save for later Item saved, go to cart PPV Articles - American Journal of Psychiatry $35.00 Add to cart PPV Articles - American Journal of Psychiatry Checkout Please login/register if you wish to pair your device and check access availability. Not a subscriber? Subscribe Now / Learn More PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development. Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.). FiguresReferencesCited byDetailsCited bySubstance Use Disorders: Confronting Addiction From Prevention to RecoveryKathleen T. Brady, M.D., Ph.D., Ned H. Kalin, M.D.6 May 2024 | American Journal of Psychiatry, Vol. 181, No. 5 Volume 181Issue 5 May 01, 2024Pages 457-459 Metrics Keywordsopioid use disorderbuprenorphinemedication for opioid use disorderdiscontinuationpharmacoepidemiologyPDF download History Received 13 October 2023 Revised 15 December 2023 Accepted 3 January 2024 Published online 6 May 2024 Published in print 1 May 2024
Referência(s)